For appropriate patients currently on maximally tolerated
statin therapy not at LDL-C goal, an oral add-on therapy can give you
the power to help1-4

UNLOCK

THE NEXT LEVEL OF
LDL-C CONTROL WITH NEXLIZET

ADD NEXLIZET: A once-daily oral therapy shown in a clinical trial to deliver1-4:
  • Significant 38% mean LDL-C reduction compared to placebo when added to maximally tolerated statin dose (P<0.001)*
  • Safety profile with most common ARs generally comparable to placebo

*LDL-C changes from baseline (LS mean) in 053 Trial: NEXLIZET: -36% (n=86); placebo: +2% (n=41) (P<0.001).

LDL-C changes from baseline (LS mean) for other drugs in the trial: bempedoic acid: -17% (n=88); ezetimibe: -23% (n=86).1

LDL-C=low-density lipoprotein cholesterol; AR=adverse reaction; LS=least squares.